早发型胎儿生长受限妊娠中产前皮质类固醇给药的最佳时机:大型多中心队列研究(OPTICORE研究)结果
本研究比较了荷兰6家三级医院2012至2021年间对早发型胎儿生长受限妊娠采用两种产前皮质类固醇给药时机的围产期和院内死亡复合结局。共纳入1453例患者,策略A组871例、策略B组582例。策略B组复合死亡率数值上较高但未达统计学显著(7.2% vs 9.8%;校正OR 1.47;95%CI 0.97-2.22,参照A组),且多数孕妇在推定治疗窗之外分娩。
要点
- 策略B组围产期和院内死亡复合结局数值上高于策略A组(7.2% vs 9.8%;校正OR 1.47;95%CI 0.97-2.22,参照A组),未达统计学显著。
- 策略B组坏死性小肠结肠炎更多(3.7% vs 7.6%;校正OR 2.18;95%CI 1.29-3.69),但呼吸窘迫综合征(39.6% vs 34.5%;校正OR 0.63;95%CI 0.45-0.88)和支气管肺发育不良(18.9% vs 17.4%;校正OR 0.69;95%CI 0.50-0.96)更少。
- 策略A组和B组分别在52.8%和53.6%的病例中于皮质类固醇2至14天治疗窗内分娩(P值 .663),给药至分娩中位时间均为6天。
核心结论
- 策略B似乎与更高的围产期和院内死亡复合结局率相关,这不能由皮质类固醇给药至分娩的时间间隔差异解释。
- 重要的是,大多数孕妇在推定的皮质类固醇治疗窗之外分娩。
- 未来研究应聚焦于改善早发型胎儿生长受限妊娠中产前皮质类固醇的时机,并识别产前和/或产后管理的其他差异以解释结局差异,鉴于该情形下新生儿发病和死亡风险高。
研究设计与样本
- 多中心回顾性队列研究,在荷兰6家三级医院于2012年至2021年间进行。
- 3家医院采用时机策略A(脐动脉搏动指数高于第95百分位且舒张末期血流正向),3家医院采用策略B(舒张末期血流缺失或反向)。
- 共纳入1453例患者,策略A组871例,策略B组582例。
- 采用混合效应分析,校正出生体重z评分和出生时孕周以比较两种时机策略。
主要发现
- 策略A组和B组皮质类固醇给药平均孕周分别为28周3天(标准差16.0天)和28周4天(标准差15.8天)。
- 策略A组和B组出生体重中位数分别为1050克(范围795,1350)和1060克(范围801,1339)。
- 围产期和院内死亡复合结局:策略B组9.8% vs 策略A组7.2%(校正OR 1.47;95%CI 0.97-2.22,参照A组),未达统计学显著。
- 策略A组和B组分别在52.8%和53.6%的病例中于皮质类固醇2至14天治疗窗内分娩(P值 .663),给药至分娩中位时间均为6天。
- 策略B组坏死性小肠结肠炎更多(7.6% vs 3.7%;校正OR 2.18;95%CI 1.29-3.69),但呼吸窘迫综合征(34.5% vs 39.6%;校正OR 0.63;95%CI 0.45-0.88)和支气管肺发育不良(17.4% vs 18.9%;校正OR 0.69;95%CI 0.50-0.96)更少;其他结局两组相似。
关键数值与推荐
- 围产期和院内死亡复合结局:策略B组9.8% vs 策略A组7.2%(校正OR 1.47;95%CI 0.97-2.22,参照A组)。
- 坏死性小肠结肠炎:策略B组7.6% vs 策略A组3.7%(校正OR 2.18;95%CI 1.29-3.69)。
- 呼吸窘迫综合征:策略B组34.5% vs 策略A组39.6%(校正OR 0.63;95%CI 0.45-0.88)。
- 支气管肺发育不良:策略B组17.4% vs 策略A组18.9%(校正OR 0.69;95%CI 0.50-0.96)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Early-onset fetal growth restriction as consequence of placental insufficiency frequently requires iatrogenic preterm birth. Administration of antenatal corticosteroids reduces risks of neonatal morbidity and mortality following preterm birth and is most beneficial if the neonate is delivered within 2 weeks following treatment. International guidelines on fetal growth restriction pregnancies do not provide directives regarding the timing of antenatal corticosteroids, resulting in practice variation. OBJECTIVE: This study compared the 2 main timing strategies of antenatal corticosteroids administration in the Netherlands for early-onset fetal growth restriction pregnancies: administration when the umbilical artery shows a pulsatility index above the 95th centile with (A) positive end-diastolic flow vs (B) absent or reversed end-diastolic velocity. STUDY DESIGN: A multicenter retrospective cohort study was performed in 6 tertiary hospitals in the Netherlands between 2012 and 2021. Three hospitals practiced timing strategy A and 3 strategy B. The primary outcome was defined as a composite of perinatal and in-hospital mortality. Secondary outcomes were in line with the core outcome set for fetal growth restriction. Mixed effects analyses were performed adjusted for birthweight z-score and gestational age at birth to compare the 2 timing strategies. RESULTS: A total of 1453 patients were included, of whom 871 and 582 were treated according to timing strategy A and B, respectively. Corticosteroids were administered at a mean gestational age of 28 weeks and 3 days (standard deviation 16.0 days) in timing strategy A and 28 weeks and 4 days (standard deviation 15.8 days) in timing strategy B. The median birthweights were 1050 (range 795, 1350) and 1060 (range 801, 1339) in timing strategy A and B, respectively. Although not statistically significant, rates of perinatal and in-hospital mortality were increased in timing strategy B infants (7.2% vs 9.8%; adjusted odds ratio 1.47; 95% confidence interval 0.97-2.22, reference A). 52.8% and 53.6% of patients in strategy A and B, respectively, delivered within the corticosteroids therapeutic window of 2 to 14 days (P value .663), with a median time between corticosteroid administration and delivery of 6 days for strategy A and 6 days for strategy B. Timing strategy B was associated with more necrotizing enterocolitis (3.7% vs 7.6%; adjusted odds ratio 2.18; 95% confidence interval 1.29-3.69), but less respiratory distress syndrome (39.6% vs 34.5%; adjusted odds ratio 0.63; 95% confidence interval 0.45-0.88) and bronchopulmonary dysplasia (18.9% vs 17.4%; adjusted odds ratio 0.69; 95% confidence interval 0.50-0.96). Other outcomes were similar between groups. CONCLUSION: Timing strategy B seemed to be associated with higher rates of the composite of perinatal and in-hospital mortality, which could not be explained by a difference in time intervals between corticosteroid administration and delivery. Importantly, most pregnant women delivered outside the presumed therapeutic corticosteroid window. Future research should focus on the improvement of the timing of antenatal corticosteroids in pregnancies complicated by early-onset fetal growth restriction and the identification of other differences in ante- and/or postnatal management to explain differences in outcomes, given the high risk for neonatal morbidity and mortality in this setting.
引用
- van de Meent M, Ganzevoort W, Gordijn SJ, et al. OPtimal TIming of antenatal COrticosteroid administration in pregnancies complicated by early-onset fetal growth REstriction: results of a large multicenter cohort study (the OPTICORE study). Am J Obstet Gynecol. 2024. PMID: 39694164. doi:10.1016/j.ajog.2024.12.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。